Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07526116
PHASE1

A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults

Sponsor: Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

This clinical study will evaluate the study drug, REGN22044, in healthy participants. REGN22044 has not previously been studied in humans. The purpose of this study is to learn: * What side effects may happen when REGN22044 is taken * How much of REGN22044 is in the blood at different times * Whether the body makes antibodies against REGN22044 (which could make the drug less effective or could lead to side effects)

Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN22044 in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2026-06-05

Completion Date

2027-02-08

Last Updated

2026-08-25

Healthy Volunteers

Yes

Interventions

DRUG

REGN22044

Administered per the protocol

DRUG

Placebo

Administered per the protocol

Locations (1)

Ghent University Hospital

Ghent, Oost-Vlaanderen, Belgium